 Tuberculosis, TB, programs rely heavily on access to quality medications at affordable prices. International suppliers like the Global Drug Facility provide essential drugs for TB treatment, but their costs can be prohibitively expensive for many countries. This study examined the drug costs and import costs associated with different TB drug regimens, finding that shorter regimens and oral only treatments tend to have lower import costs than longer regimens and those containing injectables. Additionally, the study found that increasing the number of treatment months increases the import cost of a drug regimen. These findings suggest that shorter and oral only regimens may be more financially feasible for TB programs, especially those in low-income settings. This article was authored by Stefan Kohler, Norman Sideli, J.H.R., and others.